Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 08-Dec-23 8:00 AM View:  | Sullivan Eddie Joe Chief Executive Officer Director | Sab Biotherapeutics, Inc. (SABS) | 07-Dec-23 | Private Purchase | 1,740 | $0.88 | $1,531.20 | < 1% 5.23M to 5.23M | |
| 30-Nov-23 5:00 PM View: | King Michael CHIEF FINANCIAL OFFICER | Sab Biotherapeutics, Inc. (SABS) | 30-Nov-23 | Private Purchase | 5,000 | $0.90 | $4,500.00 | 100% 0 to 5.0K | |
| 30-Nov-23 8:00 AM View: | Reich Samuel J Executive Chairman Director | Sab Biotherapeutics, Inc. (SABS) | 29-Nov-23 | Private Purchase | 11,000 | $0.89 | $9,841.70 | 1% 755.7K to 766.7K | |
| 28-Nov-23 4:05 PM View: | Moin Andrew Director | Sab Biotherapeutics, Inc. (SABS) | 24-Nov-23 | Option Exercise Duplicate | 4,584,570 | -- | -- | 100% 0 to 4.58M | |
| 28-Nov-23 4:05 PM View: | Ellias Helen K. Director | Sab Biotherapeutics, Inc. (SABS) | 24-Nov-23 | Option Exercise | 2,857,140 | -- | -- | 100% 0 to 2.86M | |
| 28-Nov-23 4:05 PM View: | Sessa Capital (master), L.P. Director | Sab Biotherapeutics, Inc. (SABS) | 24-Nov-23 | Option Exercise | 4,584,570 | -- | -- | 100% 0 to 4.58M | |
| 16-Mar-23 10:00 PM View: | Kropotova Alexandra Chief Medical Officer | Sab Biotherapeutics, Inc. (SABS) | 14-Mar-23 | Grant | 275,000 | -- | -- | 100% 0 to 275.0K | |
| 09-Dec-22 9:01 AM View: | Link David Charles Director | Sab Biotherapeutics, Inc. (SABS) | 07-Dec-22 | Grant | 41,493 | $1.21 | $49,999.10 | 262% 15.82K to 57.31K | |
| 09-Dec-22 9:02 AM View: | Spragens Jeffrey G Director | Sab Biotherapeutics, Inc. (SABS) | 07-Dec-22 | Grant | 82,987 | $1.21 | $99,999.30 | 27% 312.0K to 394.99K | |
| 09-Dec-22 4:31 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 07-Dec-22 | Grant Duplicate | 82,987 | $1.21 | $99,999.30 | 1% 8.02M to 8.1M | |
| 14-Sep-22 5:16 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 13-Sep-22 | Private Purchase | 10,000 | $0.73 | $7,297.00 | < 1% 4.98M to 4.99M | |
| 08-Sep-22 4:31 PM View: | Sullivan Eddie Joe Chief Executive Officer Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 07-Sep-22 | Private Purchase | 14,000 | $0.74 | $10,315.20 | < 1% 5.22M to 5.23M | |
| 10-Feb-23 10:00 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 07-Jun-22 | Gift | 2,000,000 | -- | -- | (20%) 10.1M to 8.1M | |
| 07-Jun-22 8:00 PM View: | Kropotova Alexandra Chief Medical Officer | Sab Biotherapeutics, Inc. (SABS) | 06-Jun-22 | Grant | 300,000 | -- | -- | 100% 0 to 300.0K | |
| 23-May-22 5:52 PM View: | Spragens Jeffrey G Director | Sab Biotherapeutics, Inc. (SABS) | 20-May-22 | Acquisition (other) | 299,002 | -- | -- | 2300% 13.0K to 312.0K | |
| 23-May-22 5:45 PM View: | Reich Samuel J Executive Chairman Director | Sab Biotherapeutics, Inc. (SABS) | 20-May-22 | Acquisition (other) | 207,001 | -- | -- | 7% 3.05M to 3.26M | |
| 23-May-22 5:45 PM View: | Reich Samuel J Executive Chairman Director | Sab Biotherapeutics, Inc. (SABS) | 20-May-22 | Disposition (other) | 2,500,130 | -- | -- | (77%) 3.26M to 755.7K | |
| 16-Nov-21 3:09 PM View: | Beyer Russell P Chief Financial Officer | Sab Biotherapeutics, Inc. (SABS) | 26-Oct-21 | Market Sale | 278 | $7.90 | $2,196.20 | (10%) 2.77K to 2.49K | (20%) |
| 16-Nov-21 3:09 PM View: | Beyer Russell P Chief Financial Officer | Sab Biotherapeutics, Inc. (SABS) | 25-Oct-21 | Grant | 129 | $7.78 | $1,003.62 | 5% 2.64K to 2.77K | 22% |
| 26-Oct-21 9:49 PM View: | Link David Charles Director | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 15,820 | -- | -- | 100% 0 to 15.82K | |
| 26-Oct-21 9:51 PM View: | Finnegan Frederick Chief Business Officer | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 38,596 | -- | -- | 100% 0 to 38.6K | |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant Duplicate | 4,974,500 | -- | -- | 98% 5.07M to 10.05M | |
| 26-Oct-21 9:49 PM View: | Link David Charles Director | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 12,097 | -- | -- | 76% 15.82K to 27.92K | |
| 26-Oct-21 9:51 PM View: | Hamilton Edward D. 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 4,974,500 | -- | -- | 100% 0 to 4.97M | |
| 26-Oct-21 9:50 PM View: | Sullivan Eddie Joe Chief Executive Officer Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 5,213,760 | -- | -- | 100% 0 to 5.21M | |
| 26-Oct-21 9:50 PM View: | Luke Thomas Charles Chief Medical Officer | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 5,428 | -- | -- | 100% 0 to 5.43K | |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant | 5,049,350 | -- | -- | 20197% 25.0K to 5.07M | |
| 26-Oct-21 9:51 PM View: | Hamilton Edward D. 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 22-Oct-21 | Grant Duplicate | 5,049,350 | -- | -- | 102% 4.97M to 10.02M | |
| 26-Oct-21 9:50 PM View: | Luke Thomas Charles Chief Medical Officer | Sab Biotherapeutics, Inc. (SABS) | 19-Oct-21 | Grant | 990 | $10.10 | $9,999.00 | 100% 0 to 0.99K | (22%) |
| 16-Nov-21 3:09 PM View: | Beyer Russell P Chief Financial Officer | Sab Biotherapeutics, Inc. (SABS) | 18-Oct-21 | Grant | 2,475 | $10.10 | $24,997.50 | 1509% 0.16K to 2.64K | (6%) |
| 26-Oct-21 9:51 PM View: | Hamilton Edward D. 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Oct-21 | Grant | 5,092 | $10.10 | $51,429.20 | 20% 25.0K to 30.09K | (22%) |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Oct-21 | Grant Duplicate | 5,092 | $10.10 | $51,429.20 | 10% 50.0K to 55.09K | (22%) |
| 15-Oct-21 10:48 AM View: | Reich Samuel J CEO and CFO Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Oct-21 | Market Purchase | 1,000 | $10.11 | $10,110.00 | < 1% 3.05M to 3.05M | (22%) |
| 15-Oct-21 10:51 AM View: | Katz Ilan Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 13-Oct-21 | Market Purchase | 500 | $10.10 | $5,052.50 | < 1% 3.05M to 3.05M | (22%) |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 13-Oct-21 | Grant Duplicate | 20,800 | $10.10 | $210,080.00 | 42% 50.0K to 70.8K | (22%) |
| 26-Oct-21 9:51 PM View: | Hamilton Edward D. 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 13-Oct-21 | Grant | 20,800 | $10.10 | $210,080.00 | 83% 25.0K to 45.8K | (22%) |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 12-Oct-21 | Grant | 25,000 | $10.09 | $252,250.00 | 100% 0 to 25.0K | (22%) |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 12-Oct-21 | Grant | 25,000 | $10.08 | $252,000.00 | 100% 25.0K to 50.0K | (22%) |
| 26-Oct-21 9:50 PM View: | Sullivan Eddie Joe Chief Executive Officer Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 07-Oct-21 | Grant | 2,800 | $10.07 | $28,196.00 | 100% 0 to 2.8K | (21%) |
| 26-Oct-21 9:48 PM View: | Hamilton Christine E Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 01-Oct-21 | Grant Duplicate | 2,695 | $10.10 | $27,219.50 | 100% 0 to 2.69K | (22%) |
| 05-Oct-21 5:00 PM View: | Spragens Jeffrey G Director | Sab Biotherapeutics, Inc. (SABS) | 01-Oct-21 | Market Purchase | 13,000 | $10.07 | $130,910.00 | 100% 0 to 13.0K | (22%) |
| 26-Oct-21 9:51 PM View: | Hamilton Edward D. 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 01-Oct-21 | Grant | 2,695 | $10.10 | $27,219.50 | 100% 0 to 2.69K | (22%) |
| 05-Oct-21 5:00 PM View: | Katz Ilan Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 01-Oct-21 | Market Purchase | 1,000 | $10.09 | $10,090.00 | < 1% 3.05M to 3.05M | (22%) |
| 16-Nov-21 3:09 PM View: | Beyer Russell P Chief Financial Officer | Sab Biotherapeutics, Inc. (SABS) | 29-Sep-21 | Grant | 10 | $10.08 | $100.80 | 6% 0.15K to 0.16K | (6%) |
| 16-Nov-21 3:09 PM View: | Beyer Russell P Chief Financial Officer | Sab Biotherapeutics, Inc. (SABS) | 28-Sep-21 | Grant | 154 | $10.08 | $1,552.27 | 100% 0 to 0.15K | (6%) |
| 14-Jan-21 1:30 PM View: | Big Cypress Holdings LLC CEO and CFO Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Jan-21 | Purchase | 417,200 | $10.00 | $4,172,000.00 | 16% 2.63M to 3.05M | |
| 14-Jan-21 1:32 PM View: | Katz Ilan Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Jan-21 | Purchase Duplicate | 417,200 | $10.00 | $4,172,000.00 | 16% 2.63M to 3.05M | |
| 14-Jan-21 1:33 PM View: | Reich Samuel J CEO and CFO Director 10% Owner | Sab Biotherapeutics, Inc. (SABS) | 14-Jan-21 | Purchase Duplicate | 417,200 | $10.00 | $4,172,000.00 | 16% 2.63M to 3.05M |
